“Persistence, Clinical and Economic Impact of Infliximab CT-P13 in Rheumatoid Arthritis, Psoriatic Arthropathy and Ankylosing Spondylitis Naïve and Switched Patients: After 5 Years of Follow-Up”, J. Pharm. Nutr. Sci., vol. 12, pp. 74–79, Dec. 2022, doi: 10.29169/1927-5951.2022.12.06.